. Author manuscript; available in PMC: 2023 Aug 1.

Published in final edited form as: Nat Rev Drug Discov. 2022 Mar 21;21(8):559–577. doi: 10.1038/s41573-022-00413-7

Table 2.

Clinical trials involving cytokines that have important roles in NK cell biology

Cytokine agonist or antagonist	Active clinical trials
IL-2 (and agonists ALKS 4230, F42K)	NCT02799095, NCT03861793, NCT04144517, NCT04592653, NCT04830124, NCT05092360
IL-12 (fusions with antibodies, encoding genetic material, and controlled release)	NCT02062827, NCT02483312, NCT03132675, NCT03567720, NCT03823131, NCT04095689, NCT04370587, NCT04471987, NCT04526730, NCT04756505, NCT04911166
IL-15 (hetIL-15, N-803)	NCT01898793, NCT02138734, NCT02452268, NCT02465957, NCT02523469, NCT02782546, NCT02890758, NCT02989844, NCT0322825, NCT03228667, NCT03387111, NCT03520686, NCT03563157, NCT04261439, NCT04290546, NCT04390399, NCT04847466, NCT04898543, NCT04927884, NCT05096663
IL-18	NCT04787042
TGF- β Inhibitors (fresolimumab, galunisertib)	NCT01582269, NCT01682187, NCT02452008, NCT02581787, NCT02672475, NCT02688712, NCT03206177, NCT04605562